Triple Negative Breast Cancer by Chetan Deshmukh
Session 4 : Triple Negative Breast Cancer
Chairpersons :
K. Pavithran, N. K. Warrier
Speaker :
Chetan Deshmukh
ABC Joint Analysis: Optimal Chemotherapy Backbone for HER2-Negative EBC: TC vs TaxAC in HER2-Negative EBC (ABC Joint Analysis): Timeline, Accrual, Treatment
Author: Joanne Lorraine Blum
Conference: 2016 ASCO Annual Meeting, Abstract 1000
Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer, A Randomized Clinical Trial
Author: Theodoros Foukakis
Reference: JAMA. 2016;316(18):1888-1896
Comparison of four cycles epirubicin and cyclophosphamide (EC) followed by four cycles docetaxel (T) versus six cycles docetaxel and carboplatin (TP) as adjuvant chemotherapy for women with operable triple negative breast cancer
Author: Peng Yuan
Conference: 2016 ASCO Annual Meeting, Abstract 1068